


CLAIMS

1. Association comprising a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent.
2. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is a compound of formula (I) :



wherein :

- X represents an oxygen or sulphur atom, or a group CH_2 or $\overset{\text{R}^2}{\text{CH}}$ (wherein R^2 together with R^2 forms an additional bond),
- R^1 and R^2 , which may be the same or different, each represent a hydrogen atom, a linear or branched ($\text{C}_1\text{-}\text{C}_6$)alkyl group, an aryl group, an aryl-($\text{C}_1\text{-}\text{C}_6$)alkyl group in which the alkyl moiety is linear or branched, an aryloxy group, an aryl-($\text{C}_1\text{-}\text{C}_6$)alkyloxy group in which the alkyl moiety is linear or branched, a linear or branched ($\text{C}_1\text{-}\text{C}_6$)alkoxy group, a hydroxy group, an amino group, a linear or branched ($\text{C}_1\text{-}\text{C}_6$)alkylamino group or a di-($\text{C}_1\text{-}\text{C}_6$)alkylamino group in which the alkyl moieties are linear or branched,
or R^1 and R^2 together form an oxo, thioxo or imino group,
it also being possible for R^2 together with R^2 to form an additional bond,
- A represents a ($\text{C}_1\text{-}\text{C}_6$)alkylene chain in which one CH_2 group may be replaced by a hetero atom selected from oxygen and sulphur or by a group NR_a (wherein R_a

represents a hydrogen atom or a linear or branched (C_1 - C_6)alkyl group, or by a phenylene or naphthylene group,

- R^3 and R^4 , which may be the same or different, each represent a hydrogen or halogen atom or a group R, OR or NRR' (wherein R and R', which may be the same or different, each represent a hydrogen atom or a linear or branched (C_1 - C_6)alkyl group, a linear or branched (C_2 - C_6)alkenyl group, a linear or branched (C_2 - C_6)alkynyl group, an aryl group, an aryl-(C_1 - C_6)alkyl group in which the alkyl moiety is linear or branched, an aryl-(C_2 - C_6)alkenyl group in which the alkenyl moiety is linear or branched, an aryl-(C_2 - C_6)alkynyl group in which the alkynyl moiety is linear or branched, a heteroaryl group, a heteroaryl-(C_1 - C_6)alkyl group in which the alkyl moiety is linear or branched, a heteroaryl-(C_2 - C_6)alkenyl group in which the alkenyl moiety is linear or branched, a heteroaryl-(C_2 - C_6)alkynyl group in which the alkynyl moiety is linear or branched, a (C_3 - C_8)cycloalkyl group, a (C_3 - C_8)cycloalkyl-(C_1 - C_6)alkyl group in which the alkyl moiety is linear or branched, or a linear or branched (C_1 - C_6)polyhaloalkyl group),
or R^3 and R^4 , together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,

- R^5 and R^6 , which may be the same or different, may have any of the meanings of R given hereinbefore,


- D represents:

a benzene nucleus, in which case X cannot represent a group $\overset{R'^2}{\underset{\downarrow}{CH}}$ as defined hereinbefore,


or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,

- B represents a linear or branched (C_1 - C_6)alkyl group or a linear or branched (C_2 - C_6)alkenyl group, those groups being substituted :

◆ by a group of formula (II) :




wherein :




5 wherein Z represents an oxygen or sulphur atom, and R and R', which may be the same or different, may have any of the meanings given hereinbefore,

- and R^8 represents an aryl group, an arylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, a heteroaryl group, a heteroarylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, CN, tetrazole, —OR, —NRR',



10 wherein Z is as defined hereinbefore, and R and R', which may be the same or different, may have any of the meanings given hereinbefore,

◆ or by a group R^9 , wherein R^9 represents a CN, tetrazole,



15 wherein Z is as defined hereinbefore, and R and R', which may be the same or different, may have any of the meanings given hereinbefore, n represents 0, 1, 2, 3, 4, 5 or 6, and R^{10} and R^{11} , which may be the same or different, each represent a hydrogen atom or a linear or branched ($\text{C}_1\text{-C}_6$)alkyl group, it being understood that R^{10} and R^{11} cannot simultaneously represent a hydrogen atom,

or B represents a group of formula (II) or a group R⁹ as defined hereinbefore,

it being understood that :

- * the oxime R⁶-C(=N-OR⁵)- can be of Z or E configuration,
- * aryl means a phenyl, naphthyl or biphenyl group, it being possible for those groups to
5 be partially hydrogenated,
- * heteroaryl means any mono- or bi-cyclic aromatic group containing 5 to 10 members, which may be partially hydrogenated in one of the rings in the case of bicyclic heteroaryls and which contains 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

10 it being possible for the aryl and heteroaryl groups thereby defined to be substituted by from 1 to 3 groups selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)polyhaloalkyl, linear or branched (C₁-C₆)alkoxy, hydroxy, carboxy, formyl, NR_bR_c (wherein R_b and R_c, which may be the same or different, each represent a hydrogen atom, a
15 linear or branched (C₁-C₆)alkyl group, an aryl group or a heteroaryl group), ester, amido, nitro, cyano, and halogen atoms,

an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base.

3. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoic acid, an enantiomer or
20 diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base.

4. Association according to claim 1, wherein the antioxidant agent is coenzyme Q₁₀.

- 5 5. Association according to claim 1, wherein the antioxidant agent is vitamin E.
6. Association according to claim 1, which is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)-(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoic acid and coenzyme Q₁₀.
7. Association according to claim 1, which is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)-(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoic acid and vitamin E.
8. Pharmaceutical compositions comprising as active ingredient a compound favouring the lipid and carbohydrate metabolisms in association with an antioxidant agent according to one of claims 1 to 7, on their own or in combination with one or more pharmaceutically acceptable excipients.
9. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.
10. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.
11. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.
12. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

13. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.
- 5 14. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.
- 10 15. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.
16. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.